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Abstract
Background: The first Multi-center Medication Reconciliation Quality Improvement Study (MARQUIS1)
demonstrated that implementation of a medication reconciliation best practices toolkit decreased total
unintentional medication discrepancies in five hospitals. We sought to implement the MARQUIS toolkit in more
diverse hospitals, incorporating lessons learned from MARQUIS1.
Methods: MARQUIS2 is a pragmatic, mentored implementation QI study which collected clinical and
implementation outcomes. Sites implemented a revised toolkit, which included interventions from these domains:
1) best possible medication history (BPMH)-taking; 2) discharge medication reconciliation and patient/caregiver
counseling; 3) identifying and defining clinician roles and responsibilities; 4) risk stratification; 5) health information
technology improvements; 6) improved access to medication sources; 7) identification and correction of real-time
discrepancies; and, 8) stakeholder engagement. Eight hospitalists mentored the sites via one site visit and monthly
phone calls over the 18-month intervention period. Each site’s local QI team assessed opportunities to improve,
implemented at least one of the 17 toolkit components, and accessed a variety of resources (e.g. implementation
manual, webinars, and workshops). Outcomes to be assessed will include unintentional medication discrepancies
per patient.
Discussion: A mentored multi-center medication reconciliation QI initiative using a best practices toolkit was
successfully implemented across 18 medical centers. The 18 participating sites varied in size, teaching status, location,
and electronic health record (EHR) platform.
We introduce barriers to implementation and lessons learned from MARQUIS1, such as the importance of utilizing
dedicated, trained medication history takers, simple EHR solutions, clarifying roles and responsibilities, and the input of
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patients and families when improving medication reconciliation.
Keywords: Medication reconciliation, Patient safety, Hospital medicine, Transitions in care, Medication errors, Quality
improvement
Background
Problem description
Medication errors are a major patient safety concern
during transitions in care and occur across all healthcare
settings. Errors arise from medication discrepancies,
defined as unexplained differences among documented
regimens across different sites of care [1]. In prior work,
we demonstrated that general medical inpatients experi-
enced on average at least one discrepancy with potential
for patient harm in either their admission or discharge
medication orders [2]. When discrepancies are uninten-
tional and unresolved, they can cause harmful adverse
drug events (ADEs) and substantially increase health
care costs [3, 4].
Medication reconciliation, defined as “a process of
identifying the most accurate list of all medications a
patient is taking … and using this list to provide correct
medications for patients anywhere within the health care
system,” is required at all care transitions to reduce
actual and potential harm caused by medication discrep-
ancies [5]. The Joint Commission (TJC) designated
medication reconciliation as a National Patient Safety
Goal (NPSG.03.06.01) in 2005, but it has proven difficult
for institutions to implement [6, 7]. At many hospitals,
the quality of medication reconciliation remains poor,
and evidence-based practice is lacking [8].
Available knowledge
To address this problem, we conducted the first Multi-
center Medication Reconciliation Quality Improvement
Study (MARQUIS1) at five US hospitals, with Agency
for Healthcare Research and Quality funding [9]. This
study consolidated medication reconciliation best prac-
tices and rigorously evaluated them in a real-world
setting [10–12]. The multifaceted intervention, including
a medication reconciliation toolkit along with mentored
implementation, reduced total but not potentially harm-
ful medication discrepancies in admission and discharge
orders [13]. Implementation was variable across sites.
Using mixed methods program evaluation and site-
driven feedback, we identified the most important
components of the intervention and many lessons for
successful implementation. Furthermore, we refined the
intervention toolkit and implementation guide and de-
veloped instructional videos, didactic presentations, and
simulation exercises. This revised toolkit plus mentored
implementation were then ready for use in a larger
number of institutions to improve medication safety
more broadly.
Rationale
MARQUIS2 built upon the MARQUIS1 project, which
predominantly relied on the Brown and Lilford patient
safety intervention framework of clinical process-ori-
ented interventions complemented by management-ori-
ented interventions [14–17]. Our rationale of the
current study was: If hospitals were to adopt the
MARQUIS2 toolkit, then medication discrepancies
would be reduced, so that patient safety at care transi-
tions would be improved.
The specific aims of MARQUIS2 were to:
 Implement the refined MARQUIS2 evidence-based
medication reconciliation toolkit at 18 diverse
hospitals, using a mentored quality improvement
(QI)
implementation model.
 Evaluate the effect of the MARQUIS2 program on
unintentional medication discrepancies.
 Inform future spread of medication reconciliation
interventions by performing an evaluation of
program implementation using the Reach,
Effectiveness, Adoption, Implementation,
Maintenance (RE-AIM) framework [18].
This manuscript describes the design of MARQUIS2,
informed by lessons learned from MARQUIS1.
Methods
Context and sites
We identified potentially interested hospitals from:
MARQUIS1 toolkit downloads from the Society of Hos-
pital Medicine (SHM) website; attendance at prior
MARQUIS1 workshops or other MARQUIS talks; par-
ticipation in other SHM mentored implementation pro-
jects; and emails sent to SHM’s members and prospect
list. Interested sites completed an application, which
asked sites to identify a site leader and QI team, the hos-
pital’s characteristics and institutional environment, ex-
perience with prior QI projects and specific medication
reconciliation efforts, a needs assessment, and their
goals, strengths, and areas for improvement. Each appli-
cation was reviewed by two mentors and presented to
the study team. Applications were rated using the
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following criteria: 1) strong institutional support, dem-
onstrated by a letter from an executive champion; 2) a
local site leader with QI knowledge, experience, and
dedicated project time; 3) an interdisciplinary QI team
with appropriate roles delineated; 4) institutional experi-
ence with successful patient safety and QI projects; 5)
local financial support and resources to collect data, in-
cluding a study pharmacist(s) with dedicated time; and,
6) intention to implement one or more intervention
components.
From 72 applications we selected 18 sites, chosen
purposefully for heterogeneity in characteristics such as
size and location. We excluded sites which had already
implemented 2 or more interventions from the
MARQUIS1 toolkit. Sites were divided into three waves
of staggered implementation based on their planned
implementation timeline, with each implementation
wave including 6 sites and lasting 18months (Fig. 1).
The first sites started mentored implementation in April
2016, and the last sites ended mentored implementation
in April 2018.
Study design
To achieve both the research and quality improvement
aims of MARQUIS2, data were collected in real time
during the intervention. Site teams entered data into
Research Electronic Data Capture (REDCap), a secure
web-based platform for data management [19]. The data
coordinating center staff were tasked with analyzing and
feeding back site-specific data to each site in real time.
Thus, data collection was achieved for research purposes
while sites were concurrently able to utilize their data
for ongoing refinement of their local QI initiatives.
Mentored implementation
Each site team included interprofessional hospital-based
members and was generally led by physician and
pharmacist co-leaders, although this varied by site. The
Fig. 1 Study timeline
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site team was responsible for the MARQUIS2 goals with
guidance from a mentor. All eight mentors were hospi-
talists recruited from several academic institutions with
experience in QI methods, mentoring healthcare profes-
sionals, and/or medication safety. They were assigned up
to three sites each. Mentors underwent an all-day orien-
tation to the MARQUIS2 project and “Mentor Univer-
sity” training at the SHM’s national office at the start of
the study [20, 21]. Senior mentors, who had experience
as implementation mentors for MARQUIS1, provided
ongoing guidance to mentors and attended each men-
tor’s first site visit and first two monthly site calls with
them. Mentors also engaged in monthly “mentor coun-
cil” calls with the principal investigator and senior men-
tors to report on site progress, discuss challenges
encountered, seek advice, and share activities associated
with successful implementation.
Based on prior mentored implementation projects,
monthly site calls and at least one site visit are critical
for a site’s success [21]. The site team and assigned
implementation mentor engaged in at least an hour-long
conference call each month for the 18-month imple-
mentation period, which focused on reviewing data col-
lection/analysis and facilitating toolkit implementation
[20, 21]. Mentors also engaged in a two-day site visit
within the first 6 months of the mentoring relationship,
specifically chosen early in the implementation period
due to lessons learned from MARQUIS1 regarding the
value of conducting site visits as early as possible.
During the site visit, the mentor directly observed the
current medication reconciliation practices, strength-
ened relationships with the site team and site executive
leadership, discussed possible interventions, and addressed
barriers to MARQUIS2 toolkit implementation. This
direct contact between sites and mentors early in the
implementation period allowed for easier identification of
barriers to implementation and garnered executive leader-
ship and other stakeholder support, facilitating successful
participation in the study.
Interventions
Differences between MARQUIS 1 and 2
Table 1 denotes the differences grouped by changes to
the toolkit, the implementation approach, and the
analysis plan. (See relevant sub-sections below.)
Site team training
All 18 sites participated in educational webinars at the
beginning of their respective implementation wave. Site
teams participated in subsequent educational webinars
on the MARQUIS2 toolkit, research data collection
responsibilities, and techniques to train other healthcare
clinicians on medication reconciliation best practices.
Webinars were recorded for those sites unable to attend
the live events. Additionally, SHM coordinated four
optional regional workshops (New York, New Jersey,
Pennsylvania, and California) for sites to learn best prac-
tices in person; 14 sites attended these in-person events.
These workshops covered: generating institutional sup-
port; training others to take a BPMH and giving them
feedback; training on discharge medication counseling;
and, identifying and overcoming barriers to implementa-
tion, sustainment, and spread. During the workshops,
site leaders could network with other site leaders and
share their experiences.
Each site identified at least one study pharmacist re-
sponsible for data collection on medication discrepancies
(see Outcome Assessment). The site pharmacists were
trained by the central study pharmacist using standard-
ized patient cases during two online webinar sessions. In
addition, throughout the intervention period, SHM and
the data coordinating center conducted training sessions
for site personnel on how to measure medication
discrepancies in a consistent way across sites over time.
Toolkit
The MARQUIS2 toolkit consists of 17 interventions to
improve medication reconciliation, grouped into eight
domains: taking the best possible medication history
(BPMH); discharge medication reconciliation and coun-
seling; clarifying roles and responsibilities; risk stratifica-
tion; health information technology improvements to
the electronic health record (EHR); improving access to
medication sources; “measure-vention”, i.e. measuring
then intervening to correct discrepancies in real time;
and, stakeholder engagement [23]. All sites were provided
an updated implementation manual, instructional videos,
presentations, and return-on-investment calculators (i.e.,
from investing in medication reconciliation personnel).
The toolkit was upgraded with changes reflecting
our experience from implementation of MARQUIS1
(Table 1) [10]. First, we developed simulated standard-
ized cases for taking BPMHs and certifying competency,
since the receipt of didactic education in BPMH-taking
did not always correlate with mastery of skills in
MARQUIS1. Second, we emphasized the value of phar-
macy technicians as “medication reconciliation assistants”
trained to take accurate medication histories [24]. Adop-
tion of such a program was associated with significant
reduction in total discrepancies at one site and spread
from that site to several others during MARQUIS1 [13].
We also learned from MARQUIS1 that medication histor-
ies are best taken as early in the hospitalization as possible,
ideally before admission orders are written, to avoid re-
work when errors are corrected. Third, we developed
more precise return-on-investment (ROI) calculations
based on MARQUIS1 study results and the literature on
the impact of harmful discrepancies. We learned that
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accurate ROI calculations are critical when gaining buy-in
from and obtaining budget approval for staffing changes
by local hospital leadership. Fourth, MARQUIS1 imple-
mentation was adversely affected by several sites concur-
rently implementing new vendor EHRs. At the time of
MARQUIS2 most sites already had established vendor
EHRs, so we focused on relatively simple changes they
could make to their existing systems, including standard-
ized note templates for medication history-takers and giv-
ing proper permissions to personnel to make medication
history changes in the EHR. Lastly, we increased our em-
phasis on the patient-centered components of the inter-
vention (e.g., patient and caregiver counseling at
discharge), with the development of tools such as clinician
scripts and worksheets. These tools were iteratively re-
fined by the Patient and Family Advisory Council (PFAC)
early in the study.
Patient and family advisory council (PFAC)
With growing evidence of the value of input from
patients and their caregivers in systems improvement
research [25, 26], we assembled a PFAC for MARQUIS2.
The PFAC consisted of a PFAC specialist who had worked
on prior projects with the principal investigator and four
additional members recruited from mentor and/or co-in-
vestigator institutions. Members were chosen based on
relevant experience as a patient or caregiver (e.g., having
suffered an adverse drug event during transitions of care)
and their ability to work collaboratively and advocate for
other patients and families. The PFAC participated in
monthly phone meetings and engaged in every aspect of
the study, including the design of patient-facing interven-
tions (such as social marketing campaigns aimed at
patients), overall study design, data collection, and inter-
pretation, dissemination, and implications of the study’s
Table 1 Differences between MARQUIS1 and MARQUIS2
Domain Specific aspect MARQUIS1 MARQUIS2
Site Selection How and when sites
were recruited
Informal process, sites identified prior
to submission of grant application
Widespread search, formal application process,
most sites identified at beginning of study period
Toolkit Best possible
medication history
(BPMH) training
Didactic materials only, including slide
presentations and videos
Didactic materials plus simulation materials with
standardized cases and role-playing to enhance learning
and verify competency
Role of staff taking
BPMH
Agnostic to type of personnel Increased emphasis on the value of pharmacy
technicians as “medication reconciliation assistants”
trained to take accurate medication histories
Return on
investment
Rudimentary calculations More precise calculations based on MARQUIS1 data
Patient counseling
tools
Didactic materials, including slide
presentations and videos
Enhanced didactic materials plus scripts and
worksheets developed with Patient and Family
Advisory Council (PFAC) input
Implementation
Approach
Site team training Webinars Webinars + 4 regional workshops
Site visits, number
and timing
2 site visits: first visit in months 5–10,
second in months 16–19
1 site visit within first 6 months
Patient-family
engagement
No formalized program Established and engaged PFAC in monthly discussions
Inter-site sharing No formalized sharing 3 peer-to-peer webinars featuring sites’ stories of
successes and challenges
Health information
technology (HIT)
Discovered significant challenges exist
with the design, implementation, and use
of HIT during medication reconciliation
processes that, together with health systems
issues, impacted medication safety
Provided guidance on how best to work with existing
HIT—e.g. allowing pharmacists to make changes to
medication lists, documenting the quality of the
medication history taken and its sources, and customizing
discharge instructions to make medication changes clear
to patients and clinicians
Analyses Intervention
assessment
Scoring system of interventions; categorization
of site-level intervention components based on
meeting minutes analyzed retrospectively; no
data on receipt of interventions at the
patient level
Prospective collection of site-level interventions based on
monthly site surveys; prospective collection of patient-level
interventions as part of data collection on discrepancies
Outcome
assessment
Total medication discrepancies with potential
for harm, involving adjudication; total medication
discrepancies
Total medication discrepancies per medication per
patient, as adopted by the Leapfrog Group [22]
Program evaluation Surveys, direct observation, interviews, focus
groups of contextual factors, intervention fidelity
RE-AIMa framework
aReach, Effectiveness, Adoption, Implementation, and Maintenance
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results. During the monthly calls, we updated the PFAC
on study progress and asked them to provide feedback on
results and guidance on needed changes.
Project management
SHM’s Center for Quality Improvement served as the
project management office, driving timelines and
program milestones for each site on a day-to-day basis.
SHM marketed the study, recruited sites to participate,
supported the evaluation and selection of applicants, and
trained program mentors at Mentor University [20, 21].
Once sites and mentors were selected, most project
management activities were managed through Ques-
Gen (QuesGen Systems, Burlingame, CA), an online
platform accessible to site teams, mentors, and SHM.
Specifically, the website housed minutes from mentor-
mentee monthly phone calls, action items, data tables
and charts displaying ongoing process and outcome
data, and anonymized benchmarking data for each
wave. Furthermore, SHM provided dashboards dis-
playing the site’s month-to-month progress towards
key milestones using stoplight color coding to indi-
cate whether the site had completed, begun working
on, or were behind on milestones.
SHM staff scheduled all recurrent calls between men-
tors and their sites as well as monthly “mentor council”
calls. SHM project managers coordinated all aspects of
the site visits. Lastly, SHM hosted quarterly peer-to-peer
webinars for sites to present their work, share their
successes and challenges, and learn from each other.
Study of the intervention
Sites were engaged for 18 months of intervention time.
During this period, sites were responsible for collecting
data, implementing interventions, submitting monthly
intervention tracking data, participating in study training
sessions for site personnel on collecting consistent data,
participating in monthly mentor calls, and hosting a site
visit from their mentor.
Outcome assessment
The primary research outcome was the total number of
unintentional medication discrepancies in admission and
discharge orders per patient, similar to MARQUIS1 [9].
Each site was commissioned to obtain a gold standard
medication history on a random sample of 22 patients
per month [27]. This sample included both control
patients and intervention patients. Intervention patients
were defined as those who received a patient-level inter-
vention (e.g. BPMH was taken in the ED by a dedicated,
MARQUIS-trained clinician) and/or a system-level
intervention (e.g. the site clarified and assigned roles and
responsibilities to different staff regarding the medica-
tion reconciliation process) implemented on the unit
where the patient was admitted. Patients were admitted
to one of several pre-specified adult, non-critical care
medical or surgical unit(s) and hospitalized long enough
to obtain a “gold standard” medication history. The
study pharmacist gathered the gold standard medication
history, separate from and in addition to any medication
reconciliation activities completed by healthcare clini-
cians for patient care. The study pharmacist’s gold
standard medication history was then compared to the
clinician-generated medication history, the admission
orders, and the discharge orders for each patient. Unin-
tentional discrepancies in orders were identified as
previously described and recorded in REDCap [9, 19].
The pharmacist also recorded the timing of the discrep-
ancy (admission vs. discharge), type (omission, additional
medication, change in dose, route, frequency, or formu-
lation), and reason (history error vs. reconciliation error)
[2]. Lastly, if applicable, they documented which patient-
level interventions each patient received.
To give ongoing feedback to sites regarding the effect of
intervention(s) on outcomes, we provided monthly data
on discrepancy rates using an on-treatment analysis of pa-
tient- and system-level interventions. De-identified dis-
crepancy data were extracted from REDCap by the data
coordinating center for this feedback. Site QI teams were
also able to access monthly reports of their progress to re-
duce medication discrepancies over time across all study
units, in the form of statistical process control charts.
In MARQUIS2, physicians did not adjudicate medica-
tion discrepancies for potential for patient harm, as this
process is labor intensive and expensive. The elimin-
ation of adjudication and the collection and merging of
patient-level administrative data from each site greatly
reduced the study costs and data collection burden,
allowing us to enroll 18 sites for the same budget as 5
sites in MARQUIS1 (Table 1). Moreover, from our
prior studies we found that improvements in potentially
harmful medication discrepancies have a similar direc-
tion and magnitude as improvements in total discrep-
ancies [28].
Sites also tracked which system-level interventions
they implemented by completing a brief monthly survey.
Through this prospective data collection of site-level in-
terventions implemented, we improved upon the process
used for MARQUIS1, in which we had retrospectively
gathered this information from monthly mentor call
minutes (Table 1). Mentors additionally encouraged sites
to collect local relevant process and outcome measures,
such as tracking the workload of pharmacists involved in
discharge counseling.
Evaluation of implementation
One of the specific aims of MARQUIS2 was the evalu-
ation of the program using the Reach, Effectiveness,
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Adoption, Implementation, and Maintenance (RE-AIM)
framework [18]. Having already conducted more inten-
sive mixed methods analyses in MARQUIS1, RE-AIM
allowed us to focus more on widespread implementation
and maintenance (Table 1). Table 2 frames the defini-
tions and data sources to measure the RE-AIM compo-
nents, which include: characteristics of hospitals that did
and did not apply; descriptive statistics of units and
services that adopted and did not adopt the intervention
at each site; unintentional medication discrepancies in
admission and discharge orders; monthly survey data of
system-level interventions in use; proportion of patients
that received patient-level interventions; and, measure-
ment of discrepancies 6 months after the intervention
period. The sustainability assessments were developed
specifically for MARQUIS2 based upon existing litera-
ture [29–33].
Planned statistical analyses
This protocol does not include reporting of outcomes.
However, we plan to use interrupted time series meth-
odology and a random effects analysis on all patients
evaluated for discrepancies across the 18 sites, similar to
those conducted for MARQUIS1 [9]. We will analyze
the primary outcome of total number of unintentional
medication discrepancies in admission and discharge
orders per patient using a Poisson regression model,
with the number of preadmission medications as a
model offset. Random effects will be included in the
regression model to account for clustering at the level of
the site (due to common practice styles or institutional
culture). Temporal trends, or improvements over time,
will be incorporated into the regression model as slopes
and treated as random effects in order to allow each site
to have a unique trend prior to the introduction of any
interventions. In this way, each site will serve as its own
control. The main outcomes of interest will be changes
in y-intercept (sudden improvements with introduction
of the intervention) and changes in slope (changes in
temporal trends after implementation begins). Im-
provements in discrepancies over time will be the re-
sult of several factors: the effectiveness of individual
intervention components (including their iterative refine-
ment), the number of components implemented, the
fidelity with which each intervention is implemented, and
the spread and sustainability of implementation on partici-
pating services and units. We plan to adjust for a limited
number of fixed, patient-level covariates based on the
prior literature and MARQUIS1: patient age, medical
versus surgical service, patient understanding of their
medications (determined by the study pharmacist using
standardized criteria [2]), and season.
To determine the effects of various intervention
components, we will conduct a secondary analysis simi-
lar to that in MARQUIS1 [9]. First, we will categorize all
system-level interventions conducted by any site by
component, including date(s) of implementation or sub-
stantial spread (to a new group of patients or clinicians),
based on the monthly site surveys. This approach is less
burdensome to site leaders than the scoring system used
in MARQUIS1. We will then analyze the data using
Poisson regression to detect sudden reductions in
unintentional medication discrepancy rates temporally
associated with each implementation or spread of each
intervention component across all sites. Additionally, we
will look at the effects of each patient-level intervention
on patients who received them versus those who did
not.
Power and sample size
We recommended that each site collect data on approxi-
mately 22 patients per month. Across all 18 sites, this
will total 7128 patients. Based on prior experience we
expected that it would take an average of 6 months of
mentorship for sites to begin implementing interven-
tions, which meant 12 months of intervention delivery in
the 18 month period of mentored implementation. Thus
we expected to have data on approximately 2376
Table 2 RE-AIM measures
Dimension Definition Application to study
Reach Absolute number, proportion, and representativeness
of individuals willing to participate in a given initiative
Number and characteristics of sites that participated, applied but were not
selected to participate, sites that were contacted but did not apply, and all
US hospitals; Number and characteristics of stakeholders within each
institution involved in the study at each participating site
Effectiveness Impact of intervention on outcomes Primary outcome: number of unintentional medication discrepancies in
admission and discharge orders per patient
Adoption Absolute number, proportion, and representativeness
of settings and agents willing to initiate the program
Description of services and units that did and did not adopt the
intervention
Implementation Fidelity to the various elements of an intervention’s
protocol
Number and type of system-level intervention components implemented;
proportion of patients that received patient-level interventions
Maintenance Extent to which a program becomes part of routine
practice; long-term effects of a program on outcomes
Discrepancy rates 6 months after the end of mentored implementation;
intervention components still in place and participating units/services 6
months after the end of mentored implementation.
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patients pre- and 4752 patients post-intervention. Power
calculations are based on our MARQUIS1 data which
showed that the (Poisson distributed) number of unin-
tentional medication discrepancies was reduced by 11%
from an average of 2.9 per patient to 2.58 per patient. In
MARQUIS2 we will have over 99% power to detect a
comparable overall effect. The study will also be pow-
ered to examine the effect of individual intervention
components. Even if an intervention component is only
introduced at a single site, we will have data on 150 pa-
tients pre-intervention and 300 patients post-interven-
tion, yielding 90% power to detect a reduction in
discrepancies from 2.9 per patient to 2.4 per patient. Fi-
nally, we will have 80% power to detect a difference be-
tween an 11% relative reduction in MARQUIS1 and a
24% reduction in the current study.
Discussion
Figure 1 displays the study timeline. The beginning of
the study was characterized by site recruitment, selec-
tion, and mentor training. The next phase was baseline
data collection by the three waves of sites, followed by
site visits and monthly mentor calls, which lasted 18
months for each wave.
The site characteristics are listed in Table 3. The 18
sites varied in hospital size, location, urbanization, aca-
demic affiliation, and EHR. Hospital size ranged from 88
to 1551 beds. With the exception of the Southwest, all
U.S. regions are represented, plus one site in Canada.
Types of hospitals and health systems ranged from pub-
licly funded safety net hospitals, to community hospitals,
to university medical centers as well as one Department
of Veterans Affairs facility. The EHRs represent those
with the largest market share nationally.
In summary, we recruited 18 diverse hospitals to par-
ticipate in the MARQUIS2 mentored implementation
study. In this large pragmatic quality improvement
study, we implemented lessons learned from mixed
methods QI studies such as MARQUIS1 on how to im-
prove interventions and the approach. We streamlined
the MARQUIS2 toolkit and placed emphasis on inter-
ventions shown to reduce harmful medication discrep-
ancies: utilizing dedicated medication history takers,
training existing staff to perform discharge medication
reconciliation and patient counseling, and clarifying
Table 3 Characteristics of participating sites
Site # Beds Region Location (Urban, Suburban,
Rural)
Teaching Status Profit Status EHR
A 534 Northeast Urban University Medical Center Non-profit Epic
B 88/160 Northeast Rural Community Teaching Non-profit Meditech
C 266 Northeast Suburban Community Hospital with Some Teaching
Opportunities
Non-profit Epic
D 255 West Urban Community Teaching Non-profit Cerner
E 563 West Suburban University Medical Center Non-profit Epic
F 638 West Urban University Medical Center Non-profit Epic
G 453 South Suburban Community Teaching Non-profit Cerner Soarian
H 836a Ontario, Canada Suburban/77% Large Urban,
11% Small pop. Centre, and
12% Rural
Community Teaching/multi-site community
hospital, partnership with McMaster Medical
school and accept learners
$500 M Budget None
I 576 West Urban University Medical Center Non-profit Epic
J 365 Northeast Suburban Community Teaching Non-profit Cerner/Allscripts
K 627 West Urban University Medical Center Non-profit Epic
L 1541 Northeast Urban University Medical Center Non-profit Epic
M 525 West Urban County - Publicly-funded safety net hospital Non-profit Epic
N 232 Northeast Suburban Community Non-teaching Non-profit Meditech
O 763 South Urban Community Teaching Non-profit Cerner - Intermed RxHX
P 850/996 South Suburban University Medical Center Non-profit Epic
Q 744 South Urban University Medical Center Non-profit Allscripts
R 112b Northeast Suburban Department of Veterans Affairs Non-profit Computerized Patient
Record System (CPRS)
a456 Acute Beds, 150 Mental Health Beds, 115 Long-Term Care Beds, 177 Complex Care Beds
b65 Sub-acute Beds, 32 Long-term Care Beds, 15 Hospice and Palliative Care Beds
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roles and responsibilities among clinical personnel [34].
We also disseminated solutions to known HIT chal-
lenges and cautioned sites on implementing new EHRs.
We incorporated a PFAC into all steps of the study,
integrating patient and caregiver stakeholders into all
phases of the research. Lastly, we improved the efficiency
of data collection. If the MARQUIS2 interventions are
successful in reducing unintentional medication discrep-
ancies, we plan to disseminate widely our findings to
improve medication safety across an even wider range of
health systems.
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